


# The 6<sup>th</sup> International Conference on Coagulopathy of Liver Disease

*Discussion, Debate, Deliberations*

**October 3<sup>rd</sup> and 4<sup>th</sup> 2015**

[www.coagulationinliverdisease.org](http://www.coagulationinliverdisease.org)



Location:  
University of Virginia Grounds  
Darden Business School  
Charlottesville, Virginia



## Scientific Committee

*Stephen Caldwell, USA*  
*Juan Carlos Garcia-Pagan, Spain*  
*Ton Lisman, Netherlands*  
*Patrick Northup, USA*  
*Marco Senzolo, Italy*  
*Paolo Simioni, Italy*  
*Armando Tripodi, Italy*

*Nicolas Intagliata, USA*  
*Sam Lee, Canada*  
*Susan Mallett, UK*  
*Robert Porte, Netherlands*  
*Neeral Shah, USA*  
*R Todd Stravitz, USA*






## Day 1- October 3, 2015

**07:00 – 08:00** – Breakfast, Registration, Exhibitors and Posters




### I. Introduction and General Concepts ~ 08:00 – 09:00

Moderators: P. Simioni  and C. Greenberg 

- 08:00–08:10 **Welcome / Past Meetings: 10 years of study - Coagulation in Liver Disease** ~ Stephen Caldwell 
- 08:10–08:30 **Hemostasis: Classical and Cell Based Models** ~ Maureen Hoffman 
- 08:30–09:00 **“John F Anderson Memorial Lecture” – Thrombosis, Hemostasis and Liver Disease – A History** ~ Adrian Reuben 

### II. Bleeding in Liver Disease I ~ 09:00 – 10:20



Moderators: N Mendez-Sanchez  and P. Northup 

- 09:00–09:20 **Bleeding prevalence, type and risk** ~ Edoardo Giannini 
- 09:20–09:40 **Platelet function, dysfunction and testing in cirrhosis** ~ Don Gabriel 
- 09:40–10:00 **Endothelial and vascular pathophysiology in liver disease** ~ Sam Lee 
- 10:00–10:20 Q&A

**10:20-10:40** Coffee Break: Exhibitors and Poster viewing

### Debate: Hyperfibrinolysis in Liver Disease ~ 10:40 – 11:20

Moderators: R. Steadman  and H. Maitland 

- 10:40–10:55 **Hyperfibrinolysis is a measurable problem in liver disease** ~ Dick Rijken 
- 10:55–11:10 **Hyperfibrinolysis is a problem that cannot easily be measured and lacks supportive evidence** ~ Ton Lisman 
- 11:10–11:20 Rebuttal and vote

### III. Bleeding in Liver Disease 2 ~ 11:20 – 12:40

Moderators: A. Farias  and Z. Henry 

- 11:20–11:40 **Bleeding related to infection and renal disease** ~ Stephen Caldwell 

11:40–12:00 **Pro-coagulant therapy: human derived factors and therapeutics** – Pratima Chowdary 



12:00–12:20 **Surgical bleeding: Perspectives on Incidence and use of procoagulants** – Robert Porte 

12:20–12:40 Q&A

**12:40-14:00** Lunch: Exhibitors and Poster reviews





### Debate: Measures of coagulopathy in cirrhosis 14:00 – 14:40

Moderators: J. Gorham  and T. Lisman 

- 14:00–14:15 **Point of care tests can predict bleeding risk and guide therapy** ~ Susan Mallet 
- 14:15–14:30 **Current tests cannot predict bleeding risk, nor effectively guide therapy** ~ Neeral Shah 
- 14:30–14:40 Rebuttal and vote

### IV. New Concepts in Coagulation 14:40 – 17:10

Moderators: A. Gatt  and N. Intagliata 

- 14:40–15:10 **The pro and anticoagulant properties of microparticles** ~ Nigel Key 
- 15:10–15:40 **Immunothrombosis** ~ Craig Jenne   
~ Break (10) ~
- 15:50–16:20 **Liver injury and intrahepatic coagulation** ~ James Luyendyk 
- 16:20–16:50 **Coagulopathy and liver disease in veterinary medicine** ~ Cynthia Leveille-Webster 
- 16:50–17:10 Q&A

17:10-17:30 **Special Lecture: Early Cirrhosis after HCV Eradication: Is there a role for anti-coagulation?** ~ Zach Henry 

### V. Key note lecture (*dinner to be served*) 19:00 – 21:00

19:00: Introduction: Caldwell  and Simioni 


**Topic: Non-cirrhotic Portal Vein Thrombosis: Perspectives in 2015** ~ Dominique Valla 

## DAY 2 – October 4, 2015

**07:00 – 08:00** – Breakfast, Registration, Exhibitors and Posters

### VI. Hypercoagulability in Liver Disease ~ 08:00 – 09:40

*Moderators: E. Villa  and N. Shah *

08:00–08:20 **Mechanisms of hypercoagulability in cirrhosis** ~ Charles Eby 

08:20–08:40 **Coagulopathy in acute liver failure** ~ Todd Stravitz 

08:40–09:00 **Hypercoagulability and Vascular Disease in NASH** ~ Helena Cortez-Pinto 

09:00–09:20 **Beyond thrombin generation: fibrin clot** ~ Ton Lisman 

09:20–09:40 Q&A

### Debate 3: Intrahepatic activation of hemostasis ~ 09:40 – 10:20

*Moderators: C. Lackner  and Y. Ikura *

09:40–09:55 **Parenchymal Extinction: the means to progression of chronic liver disease** ~ Ian Wanless 


09:55–10:10 **Thrombotic liver atrophy: An unproven hypothesis** ~ David Kleiner 


10:10–10:20 Rebuttal and vote

**10:20 – 10:40** Coffee Break: Exhibitors and Poster viewing


### VII. Thrombosis in patients with liver disease 10:40 – 12:00

*Moderators: S. Lee  and A. Farias *

10:40–11:00 **Inherited hypercoagulability in cirrhosis: important or not?** ~ Juan Carlos Garcia-Pagan 

11:00–11:20 **Post-transplant thrombotic disease: pediatrics to adults** ~ Shawn Pellitier 

11:20–11:40 **Medical treatment and prophylaxis of VTE in cirrhosis** ~ Nicolas Intagliata 


11:40–12:00 **Consequences of modulating portal vein flow in cirrhosis** ~ Saher Sabri 

12:00–12:20 Q&A


**12:20 – 13:30** Lunch: Exhibitors and Poster reviews

### VIII. PVT and hepatic vein obstruction in cirrhosis 13:30 – 14:50

*Moderators: M. Magnusson  and S. Caldwell *

13:30–13:50 **Natural history of portal vein thrombosis in cirrhosis** ~ Marco Senzolo 

13:50–14:10 **Diagnosing PVT with certainty: modalities and accuracy** ~ Gia De Angelis 

14:10–14:30 **Perspectives on management of Budd-Chiari** ~ Pierre-Emmanuel Rautou 


14:30–11:50 Q&A

**14:50 – 15:10** Coffee Break: Exhibitors and Poster viewing

### Debate 4: Portal Vein Thrombosis in Cirrhosis: Treat or Not 15:10 – 15:50

*Moderators: D. Maluf  and M. Senzolo *

15:10–15:25 **Treating PVT in cirrhosis: Treatment can improve the outcome** ~ Michael Englesbee 

15:25–15:40 **Treating PVT in cirrhosis: Treatment adds risk without proven benefit** ~ Patrick Northup 

15:40–15:50 Rebuttal and vote

### IX. Conclusion and adjournment 16:00

❖ Discussion: Relevant aims, clinical research and future collaborations

## Location

This course is being held in Charlottesville, VA. Darden Business School with its beautiful Grounds and Inn@Darden is a perfect location for our growing meeting with a world class fitness facility right next door. The GPS address is 100 Darden Boulevard, Charlottesville, VA. Take advantage of Charlottesville wonderful surroundings explore many vineyards in close proximity, or historic sites such as Thomas Jefferson's Monticello, James Monroe's Ashlawn, or James Madison's Montpelier. For more information and to plan before/after – meeting activities visit [www.visitcharlottesville.org](http://www.visitcharlottesville.org)

## Registration

Registration is available only online at [www.cmevillage.com](http://www.cmevillage.com) and click on “Live Conferences”. Registration fees for this conference include continental breakfast, refreshments during breaks, lunch and syllabus materials and Friday evening reception.

## Registration fees

	<u><a href="#">Until 8/28/2015</a></u>	<u><a href="#">8/29-9/20</a></u>	<u><a href="#">9/21</a></u>
<b>and later</b> Physicians:	\$295	\$395	\$475
Other HealthCare Professionals:	\$50	\$100	\$150
Resident/ Fellow:	\$50	\$50	

## Lodging

A block of rooms has been reserved for course participants at The Inn@Darden conveniently located only few steps from our meeting spaces. Charlottesville, VA. To reserve your accommodation please call 434.243.5000 and identify yourself as a participant in the “**Liver Disease Conference**” to ensure that you receive the preferred conference rate. **Based on availability the room rates will be honored three (3) days prior and following the event dates – perfect for your extended weekend stay.**

**Reservations must be made by Friday, August 28, 2015** to ensure the conference preferred rate. Any reservations made after 8/28/2015 will be made on a space and rate available basis only. Conference lodging rates are subject to 11% Charlottesville Hotel tax addition to the published rate: Hotel Room \$135.00/night. Please book your room early as our block may sell out before the deadline.

## Accreditation and Designation statement

The University of Virginia, School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Virginia, School of Medicine designates this educational activity for a maximum of **14 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## Hours of participation statement

The University of Virginia School of Medicine awards hours of participation (equivalent to AMA PRA Category 1 Credits.TM) to each non-physician participant who successfully completes this educational activity. The University of Virginia School of Medicine maintains a record of participation for six (6) years.

## Confirmation & Cancellation Policy

Upon receipt of registration and payment, you will receive an email confirmation. Registration fees will be refunded (less a \$50 administrative fee) for cancellations received a minimum of 14 days prior to the activity date. No refunds will be granted for registration fees of less than \$50 or for cancellations made within 13 days of the activity. The University of Virginia School of Medicine reserves the right to cancel CME activities if necessary. In this case, reimbursement of registration fees will not assess the \$50 administrative fee. All other expenses incurred associated with this CME activity are the sole responsibility of the participant.

## Disclosure of faculty financial affiliations

The University of Virginia School of Medicine, as an ACCME accredited provider, endorses and strives to comply with the Accreditation Council for Continuing Medical Education (ACCME) Standards of Commercial Support, Commonwealth of Virginia statutes, University of Virginia policies and procedures, and associated federal and private regulations and guidelines on the need for disclosure and monitoring of proprietary and financial interests that may affect the scientific integrity and balance of content delivered in continuing medical education activities under our auspices. The University of Virginia School of Medicine requires that all CME activities within this institution's ACCME accreditation status be developed independently and be scientifically rigorous, balanced and objective in the presentation/discussion of its content, theories and practices. All faculty presenters participating in an accredited CME activity are expected to disclose relevant financial relationships with commercial entities occurring within the past 12 months (such as grants or research support, employee, consultant, stock holder, member of speakers bureau, etc.). The University of Virginia School of Medicine will employ appropriate mechanisms to resolve potential conflicts of interest to maintain the standards of fair and balanced education for the participants. Questions about specific strategies can be directed to the Office of Continuing Medical Education, P.O. Box 800711, University of Virginia School of Medicine, Charlottesville, Virginia. The faculty and staff of the University of Virginia Office of Continuing Medical Education have no financial affiliations to disclose. Disclosure of discussion of non-FDA approved uses for pharmaceutical products and/or medical devices The University of Virginia School of Medicine, as an ACCME accredited provider, requires that all faculty presenters identify and disclose any off-label uses for pharmaceutical and medical device products. The University of Virginia School of Medicine recommends that each physician fully review all the available data on new products or procedures prior to clinical use. The University of Virginia Office of Continuing Medical Education requires that all participants at live CME activities sign attendance sheets daily to confirm participation in the CME activity for that day.

## Special Needs

The Americans with Disabilities Act of 1990 requires that all individuals, regardless of their disabilities, have equal access. The Office of Continuing Medical Education at the University of Virginia School of Medicine is pleased to assist participants with special needs. Written requests must be received 30 days prior to the conference date. These should be mailed to UVA Office of Continuing Medical Education, Box 800711, Charlottesville, VA 22908 or to [uvacme@virginia.edu](mailto:uvacme@virginia.edu).

## Contact information

**Eva Casola**

CME Program Manager, Office of Continuing Medical Education, School of Medicine, University Of Virginia

[EvaC@virginia.edu](mailto:EvaC@virginia.edu) 434-924-1657